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Purpose: To evaluate the efficacy and safety of Ahmed Glaucoma Valve (AGV) 
implantation with adjunctive use of preserved amniotic membrane for surgical 
management of refractory glaucoma.
Methods: Seven patients (5 female subjects) with refractory glaucoma were included 
in the study. An AGV (model FP7) was implanted in the usual manner and was 
covered with two layers of cryopreserved human amniotic membrane. Intraocular 
pressure (IOP) and number of glaucoma medications before and after surgery, and 
complications were evaluated.
Results: Mean duration of follow-up was 16.8±4.6 months. Mean preoperative IOP 
was 31.7±4.4 mmHg which was reduced to 17.7±6.1 mmHg at final follow-up (P=0.01, 
Wilcoxon U test). Although the number of topical medications was also reduced 
(mean decrease of 0.85 drops), this decrease was not significant (P=0.10, Wilcoxon 
U test). None of the eyes developed encapsulation after surgery; only one case was 
complicated by posterior migration of the implant resulting in failure.
Conclusion: Glaucoma shunt surgery using the AGV with adjunctive amniotic 
membrane seems to be a safe and effective procedure which may reduce the risk of 
bleb encapsulation in refractory glaucomas.
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INTRODuCTION
Glaucoma drainage devices (GDDs) and 
cyclodestructive procedures are the usual 
surgical options in patients with multiple 
previous glaucoma operations.1 Implanting 
GDDs in eyes with scarred or thin conjunctiva 
due to prior surgical procedures is difficult 
and may entail serious complications with 
unfavourable long-term results.2 Amniotic 
membrane (AM) has anti-inflammatory, 
antifibrotic, and antiangiogenic properties3, 
and can improve epithelialization of the ocular 
surface and act as an inhibitor of fibrosis.4 
These features theoretically make the AM an 
ideal adjuvant in trabeculectomy and shunting 
procedures to reduce fibrosis. Recently, there 
have been promising results with application 
of AM during trabeculectomy in both animal5 
and human subjects6-8. In an experimental study, 
Barton et al5 examined conjunctival specimens 
from 24 albino rabbits that had undergone 
glaucoma filtration surgery with AM. Compared 
with unoperated conjunctiva, significantly 
less fibroblast outgrowth was found in tissue 
cultures of AM transplantation explants.
A review of the literature shows that the 
application of AM during shunting procedures AGV with Amniotic Membrane; Amini et al
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is still obscure. In this study, we introduce the 
adjunctive use of amniotic membrane for GDD 
implantation and report its safety and efficacy 
in refractory glaucomas.
METHODS
Patients with refractory glaucoma in whom 
previous trabeculectomy procedures had failed 
were included in this study. All patients had 
intraocular pressure (IOP) exceeding 22 mmHg 
with maximally tolerated medications. Exclusion 
criteria were previous glaucoma shunt surgery, 
previous scleral buckling, and anterior staphyloma 
in the superotemporal quadrant. All subjects 
underwent implantation of an Ahmed Glaucoma 
Valve (AGV) model FP7 (New World Medical 
Inc., Rancho Cucamonga, USA) through a fornix-
based incision in the superotemporal quadrant. 
The implant was fixed 9 to 10 mm posterior to the 
surgical limbus with two 9-0 nylon sutures. The 
tube was then inserted into the anterior chamber 
through a 23-gauge needle track. After covering 
the tube with a scleral patch graft, the shunt plate 
was covered with two layers of cryopreserved 
human amniotic membrane, stromal side down, 
without any sutures. The conjunctiva was repaired 
using 10-0 nylon sutures.
All patients were visited one day, 1 week, 
and 1, 3 and 6 months after the procedure, and 
every 6 months thereafter. Pre- and postoperative 
IOP, the number of topical medications before 
and after surgery, and complications were 
recorded. Surgical success was defined as 
IOP of 5 to 22 mmHg with or without use 
of medications. Failure was defined as IOP 
higher than 22 mmHg with medications or an 
IOP lower than 5 mmHg on two consecutive 
visits, or signs of hypotony maculopathy. Bleb 
encapsulation was diagnosed in the presence of 
increased IOP, patency of the tube (documented 
by an elevated bleb), and slit-lamp confirmation 
of fibrous encapsulation over the shunt plate 
at least 1 month after surgery.
Descriptive statistics were used to report 
demographic characteristics using the SPSS 
software package version 14.5 (SPSS Inc., 
Chicago, USA). Wilcoxon U test was used for 
comparing variables before and after surgery.
RESuLTS
Seven patients (including 5 female subjects) with 
mean age of 18.4±18.3 (range, 1-50) years were 
operated and followed for 16.8±4.6 (range, 9-22) 
months (Table 1). Mean preoperative IOP was 
31.7±4.4 mmHg which was reduced to 17.7±6.1 
mmHg at final follow-up (P=0.01, Wilcoxon U 
test). There was a decrease in the mean number 
of topical medications from 2.42 preoperatively 
to 1.57 after surgery (mean decrease of 0.85 
drops). However, this reduction was not 
statistically significant (P=0.10, Wilcoxon U 
test). No case of encapsulation was observed 
during the follow-up period. Only one eye 
was complicated by posterior migration of the 
implant which resulted in shunt failure (success 
rate, 85.6%). Another minor complication was 
a small Descemet membrane detachment which 
required no intervention.
DISCuSSION
The history of aqueous shunts dates back to 
more than 100 years ago with the use of a range 
of materials to accomplish artificial translimbal 
or transscleral drainage of aqueous humor.9,10
Amniotic membrane is now used in 
a  wide  variety  of  medical  conditions. 
The membrane contains a host of growth 
factors, anti-inflammatory cytokines and 
antiangiogenic factors which promote epithelial 
cell proliferation and wound healing, and at 
the same time suppress inflammation and 
neovascularizaton.10,11
There are several reports on the efficacy 
of AM application during trabeculectomy.5-8 
Sheha et al8 showed that in refractory glaucoma, 
trabeculectomy combined with mitomycin C 
(MMC) and amniotic membrane transplantation 
had  higher  success  rates,  lower  mean 
postoperative IOPs, and lower complication 
rates compared to trabeculectomy with MMC 
alone. Drolsum and associates1 evaluated the 
results of amnion-shielded trabeculectomy 
with concomitant use of mitomycin C. They 
suggested this procedure as an option in cases 
with previously failed filtering surgery with 
thin or scarred conjunctiva.AGV with Amniotic Membrane; Amini et al
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The benefit of antifibrotic agents used as 
adjuncts to GDDs is controversial. According 
to the Cochrane Review on aqueous shunts12, 
among three randomized controlled clinical 
trials, two concluded that antifibrotic agents 
(e.g., MMC) have no beneficial long-term effect 
when used with aqueous shunts. Only Duan 
et al13 concluded that adjunctive MMC used 
with the Hunan aqueous device is associated 
with better success rates. However, as noted 
in the Cochrane Review, this study suffers 
from several methodological flaws. Minckler 
et al10 stated that there is no benefit in using 
antifibrotic agents as adjuncts to aqueous shunt 
procedures10.
The seven patients included in the current 
report were all high-risk surgical candidates 
in whom previous procedures had failed 
and all except one, showed considerable IOP 
reduction and a decrease in the number of 
glaucoma medications. The success rate of 
85.6% is comparable to the highest success rates 
reported for AGV implants.14-16 The cumulative 
probability of success was 87% at 1 year and 
75% at 2 years in the study by Huang et al14; 
87% at 1 year and 82% at 2 years in the report 
by Topouzis et al15; and 82.9% at 1 year in the 
study by Tsai et al16. The success rate observed 
in our results may be attributed to addition 
of amniotic membrane to standard shunting 
procedure.
Some degree of fibrous encapsulation is 
expected to develop around most GDDs. This 
encapsulation is more severe and has an earlier 
onset with the AGV implant as opposed to 
Baerveldt or Molteno shunts16 in which filtration 
is delayed due to tube ligation; this may reflect 
the effect of immediate aqueous filtration on 
fibrous encapsulation.
Bleb encapsulation, months after surgery, 
is particularly frustrating and rarely responds 
to needling (with or without fluorouracil 
injections) or surgical bleb revision with 
antimetabolites. Frequently, an additional 
glaucoma procedure, such as implanting 
another drainage device inferonasally, or laser 
cyclodestruction is necessary.2,9,16 Tsai et al16 
investigated the outcomes of Baerveldt and 
Ahmed implants for treatment of refractory 
glaucoma. Complications associated with both 
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1 1 M Congenital OD Trabeculotomy,
Trabeculectomy
- 28 3 18 - 26 2 under
conjunctiva
Posterior 
migration of 
implant
2 16 F Juvenile OS Twice Trabeculectomy 20/200 30 2 19 20/60 18 2 good Descemet 
detachment
3 6 F Aphakic OD Lensectomy
Trabeculectomy
- 34 3 18 20/200 20 2 good -
4 36 F Secondary 
(traumatic)
OD Repaired Corneal Laceration, 
Lensectomy, PK
20/200 26 3 9 20/400 20 - good -
5 17 F Congenital OD Trabeculotomy,
Trabeculectomy
20/30 38 2 22 20/30 19 3 good -
6 50 F CACG OS Cataract Extraction,
Twice Trabeculectomy
20/60 36 2 20 20/60 15 2 tube-iris 
touch
-
7 3 M Congenital OD Trabeculotomy,
Trabeculectomy
- 30 2 12 6 - good -
Table 1. Characteristics of patients undergoing Ahmed glaucoma valve implantation with amniotic membrane
OD, right eye; OS, left eye; Pre-op, preoperative; BCVA, best corrected visual acuity; IOP, intraocular pressure; F/U, follow-up; Post-
op, postoperative; M, male; F, female; CACG, chronic angle closure glaucoma; PK, penetrating keratoplastyAGV with Amniotic Membrane; Amini et al
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implants included choroidal effusions, clinical 
bleb encapsulation, and other postoperative 
complications resulting in surgical failure 
such as suprachoroidal hemorrhage, tractional 
retinal detachment, endophthalmitis, and 
malignant glaucoma. The Ahmed implant had 
a higher incidence of encapsulation (29 of 48 
patients; 60.4%) and earlier mean time to initial 
observation of encapsulation (50.0±43.8 days)16. 
None of the patients in our study developed 
bleb encapsulation during a mean follow-up 
period of 16.8 months. Similar to our results, 
were those of Eliezer et al4 who compared the 
safety and efficacy of AM in trabeculectomy 
for treatment of primary open-angle glaucoma. 
They, too, reported an encapsulated bleb in 
one eye in the AM group versus 3 eyes in 
the control group. These observations may 
be due to the fact that AM contains a host of 
growth factors, anti-inflammatory cytokines, 
and antiangiogenic factors which promote 
epithelial cell proliferation and wound healing, 
and at the same time suppress inflammation 
and neovascularization.12
One limitation of our study is the small 
sample size. Another might be that there was a 
wide age range of glaucoma types and patient 
age. Although the duration of follow-up was 
relatively long, these limitations make it difficult 
to draw a definite conclusion. Considering the 
results of this study and promising results of 
trabeculectomy with AM transplantation1,6-8, 
AGV implantation with amniotic membrane 
transplantation can be considered as an option 
for surgical treatment of refractory glaucomas. 
However, these preliminary findings should be 
confirmed by future investigations.
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